Alavert D XR Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Alavert D XR Availability in 2026

If your patients are reporting difficulty finding Alavert D XR (Loratadine 5 mg / Pseudoephedrine Sulfate 120 mg extended-release), they're not imagining it. While there is no formal shortage listed by the FDA or ASHP as of early 2026, this combination allergy-decongestant product has become increasingly difficult for patients to locate at retail pharmacies.

This briefing covers the current supply landscape, prescribing implications, cost and access considerations, and tools to help your patients find their medication.

Product Overview

Alavert D XR is an OTC behind-the-counter combination product containing:

• Loratadine 5 mg — second-generation H1 antihistamine
• Pseudoephedrine Sulfate 120 mg — sympathomimetic nasal decongestant

The extended-release formulation provides 12 hours of symptom relief for allergic rhinitis with nasal congestion. It is indicated for adults and children 12 years and older. Equivalent products include Claritin-D 12 Hour and generic Loratadine-D 12 Hour.

For a detailed mechanism review, see how Alavert D XR works.

Supply Timeline and Current Status

Key supply dynamics affecting Alavert D XR and equivalent Loratadine/Pseudoephedrine products in 2026:

• No FDA/ASHP shortage — Loratadine/Pseudoephedrine is not on any official shortage list as of March 2026
• CMEA regulatory burden — all pseudoephedrine products require behind-the-counter storage, ID verification, and sales logging under the Combat Methamphetamine Epidemic Act, which limits pharmacy stocking volume and patient convenience
• Seasonal fluctuations — availability drops sharply during spring (March–May) and fall (September–November) allergy peaks, compounded by cold/flu season demand in winter months
• Manufacturer scale — Alavert D XR is produced by Foundation Consumer Brands (ANDA076050), a smaller manufacturer with more limited distribution compared to Bayer's Claritin-D franchise
• Pharmacy stocking preferences — many chains prioritize Claritin-D and store-brand generics over Alavert D XR, making the specific brand harder to find

Prescribing Implications

Since Alavert D XR is an OTC product, prescribing considerations center on patient counseling rather than prescription management:

When Patients Report Difficulty Finding It

• Recommend the generic — Loratadine/Pseudoephedrine 5 mg/120 mg ER tablets are bioequivalent and more widely stocked at $8–$15 per box
• Clarify interchangeability — many patients don't realize Alavert D XR, Claritin-D 12 Hour, and generic Loratadine-D are the same medication
• Address the behind-the-counter barrier — some patients find the ID requirement and purchase limits confusing or inconvenient; reassure them this is standard for all pseudoephedrine products

When to Consider Prescription Alternatives

If OTC options are insufficient or consistently unavailable, consider:

• Intranasal corticosteroids (Fluticasone, Mometasone) — first-line for persistent allergic rhinitis per current guidelines
• Combination nasal sprays (Dymista — Azelastine/Fluticasone) — for patients needing both antihistamine and anti-inflammatory effects
• Oral antihistamines (Cetirizine, Fexofenadine, Levocetirizine) — if congestion is not the primary complaint
• Ipratropium nasal spray — for rhinorrhea-predominant symptoms

For a patient-facing comparison of alternatives, see alternatives to Alavert D XR.

Contraindications to Review

When counseling patients on Loratadine/Pseudoephedrine products, confirm they do not have:

• Current or recent (within 14 days) MAO inhibitor use
• Narrow-angle glaucoma
• Urinary retention
• Severe hypertension or coronary artery disease
• Hepatic or renal impairment (dose adjustment may be needed)

A comprehensive drug interaction reference is available at Alavert D XR drug interactions.

Availability Picture

Current retail availability patterns for Loratadine/Pseudoephedrine 12-hour products:

• Chain pharmacies (CVS, Walgreens, Rite Aid) — typically stock Claritin-D and store-brand generics; Alavert D brand availability varies by location
• Grocery store pharmacies (Kroger, Publix, H-E-B) — often carry store-brand Loratadine-D; may see less traffic and better stock levels
• Warehouse clubs (Costco, Sam's Club) — carry large-quantity generic packs at competitive pricing
• Independent pharmacies — variable stock, but often willing to special-order; may carry less-common brands

Cost and Access Data

Pricing for patients paying cash (no insurance, typical 2026 pricing):

• Alavert D XR (brand) — $12–$22 / 12–24 tablets
• Claritin-D 12 Hour (brand) — $15–$30 / 12–24 tablets
• Generic Loratadine-D 12 Hour — $8–$15 / 12–24 tablets

Key access notes:

• OTC product — not typically covered by commercial or government insurance
• FSA/HSA eligible
• Coupon platforms (GoodRx, SingleCare) may offer additional discounts at participating pharmacies
• No patient assistance programs exist for this product class (pricing is already accessible)

Tools and Resources for Your Practice

Help your patients find their medication faster:

• Medfinder for Providers — a free tool that checks real-time pharmacy stock for specific medications. Share this with patients who are struggling to find Alavert D XR or its equivalents.
• Patient education resources — direct patients to how to find Alavert D XR in stock and how to save money on Alavert D XR

Looking Ahead

Key trends to watch for Loratadine/Pseudoephedrine availability in 2026 and beyond:

• Generic expansion — continued growth of store-brand OTC allergy products should improve overall availability
• CMEA reform discussions — ongoing debate about whether electronic tracking systems could replace or supplement current behind-the-counter requirements
• Seasonal preparedness — consider proactively counseling patients before peak allergy seasons to stock up or identify alternative options
• Telehealth integration — OTC recommendation consultations are increasingly available via telehealth platforms, improving access for patients in underserved areas

Final Thoughts

While Alavert D XR is not in formal shortage, the practical reality for patients is that finding this specific brand can be challenging. As a provider, the most impactful steps you can take are:

1. Educating patients that generic Loratadine-D and Claritin-D are identical products
2. Sharing tools like Medfinder to help patients check pharmacy stock
3. Proactively discussing alternatives when patients report difficulty finding their preferred product
4. Considering prescription options when OTC products are insufficient or consistently unavailable

For more provider-focused resources, see our guide on how to help your patients find Alavert D XR in stock.